Tag: therapy

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

The report indicates >25 clinical trials, with the highest phase being Phase II/III as of June 2025. The US and China lead with >20 trials. Gamma Delta T Cell therapy, promising in treating blood cancers like AML, faces challenges in solid tumors. TC Biopharm's OmnImmune and TCB008 show potential, highlighting advances in this novel immunotherapy domain.

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Transparency Notification from Shareholders